Adaptive Trials for Non-Statisticians
Adaptive trials provide a compelling option to improve clinical development by allowing better pre-planning, higher efficiency, and accelerate time to market.
It's critical for all trial stakeholders- not just statisticians- to be fully aware of the potential and limitations of adaptive trials in different contexts.
In this webinar, Cytel Principal Natasa Rajicic will arm non-statistical stakeholders with the knowledge they need to make more informed decisions about applying adaptive trials in their organizations.
Key learning points include:
- The adaptive concept,
- The potential beneficial outcomes
- Types of adaptive trials and the scenarios in which they can be applied.
- Practical case studies
Attendees will leave the webinar with a strong grounding in the adaptive concept to better inform their discussions and decisions about applying adaptive methods within their own clinical programs.
Natasa Rajicic, Principal, Cytel Strategic Consulting
Natasa Rajicic has been a practicing biostatistician for over 20 years. At Cytel, she helps clients explore and apply appropriate study designs and address difficult clinical development problems. Her experiences range from studies employing advanced methods to dose escalation to late-stage regulatory interactions on product development issues. Prior to Cytel, Natasa was a biostatistician at Pfizer in New York where she provided statistical reviews of business opportunities and due diligence evaluations, and oversaw statistical input on regulatory interactions related to submissions, label extensions and negotiations, and product safety inquiries. Earlier in her career, Natasa was a statistician at the Center for Biostatistics in AIDS Research in Boston. Natasa teaches Research Design at the Columbia University’s Applied Analytics graduate program.